SCHEMBL2863200

SCHEMBL2863200

Cc1ccnc(Nc2cccc(-c3cnc(CCc4ccc(NC(=O)CO)cc4)s3)n2)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 6/20 0.48
KARS1 Q15046 8/20 0.45
NPC1 O15118 3/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
MEN1 O00255 2/20 0.41
MAPT P10636 2/20 0.41
KMT2A Q03164 2/20 0.41
MAPK1 P28482 1/20 0.41
RAB9A P51151 2/20 0.39
MAPK8 P45983 1/20 0.38
GSK3A P49840 1/20 0.38
MAPK10 P53779 1/20 0.38
HIPK1 Q86Z02 1/20 0.38
RIOK2 Q9BVS4 1/20 0.38
SNRK Q9NRH2 1/20 0.38
KDR P35968 1/20 0.38
KDM4E B2RXH2 1/20 0.37
ALDH1A1 P00352 1/20 0.37
LMNA P02545 1/20 0.37
HTT P42858 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13136241 0.91 NPC1 (0.50) SYKKARS1NPC1SMN1; SMN2MEN1
SCHEMBL2865498 0.88 KARS1 (0.49) SYKKARS1NPC1MEN1KMT2A
SCHEMBL2862312 0.86 SYK (0.52) SYKKARS1KDR
SCHEMBL2869423 0.86 KARS1 (0.49) SYKKARS1NPC1MEN1KMT2A
SCHEMBL13136273 0.85 SYK (0.51) SYKKARS1KDR
SCHEMBL13136243 0.84 KARS1 (0.46) SYKKARS1MEN1MAPTKMT2A
SCHEMBL13136183 0.84 SYK (0.49) SYKKARS1KDR
SCHEMBL13136239 0.84 KARS1 (0.54) SYKKARS1NPC1MEN1KMT2A
SCHEMBL2871117 0.83 KARS1 (0.49) SYKKARS1NPC1RAB9AKDM4E
SCHEMBL13136229 0.83 SYK (0.52) SYKKARS1KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7803801-B2 Aminopyridine compounds having Syk inhibitory activity JAPAN TOBACCO, INC. (JP) 2010-09-28 US claimed
EP-1854793-A1 NOVEL AMINOPYRIDINE COMPOUND WITH Syk INHIBITORY ACTIVITY Japan Tobacco, Inc. (JP) 2007-11-14 EP claimed
US-20060205731-A1 Novel aminopyridine compounds having Syk inhibitory activity JAPAN TOBACCO INC. (JP) 2006-09-14 US claimed
US-7803801-B2 Aminopyridine compounds having Syk inhibitory activity JAPAN TOBACCO, INC. (JP) 2010-09-28 US disclosed
US-7803801-B2 Aminopyridine compounds having Syk inhibitory activity JAPAN TOBACCO, INC. (JP) 2010-09-28 US disclosed
US-7803801-B2 Aminopyridine compounds having Syk inhibitory activity JAPAN TOBACCO, INC. (JP) 2010-09-28 US disclosed
EP-1854793-A1 NOVEL AMINOPYRIDINE COMPOUND WITH Syk INHIBITORY ACTIVITY Japan Tobacco, Inc. (JP) 2007-11-14 EP disclosed
US-20060205731-A1 Novel aminopyridine compounds having Syk inhibitory activity JAPAN TOBACCO INC. (JP) 2006-09-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060205731-A1 Novel aminopyridine compounds having Syk inhibitory activity SYK, BTK, ZAP70 SYK 1/4885KARS1 2175/4885NPC1 4496/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.